Fibrosis and carcinoid syndrome: From causation to future therapy

Nature Reviews Endocrinology

Volumn 5, Issue 5, 2009, Pages 276-283

  Druce, Maralyn ^a   Rockall, Andrea ^a   Grossman, Ashley B ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CYPROHEPTADINE; KETANSERIN; OCTREOTIDE; ONDANSETRON; RANITIDINE; SEROTONIN; SOMATOSTATIN DERIVATIVE; TACHYKININ; TRANSFORMING GROWTH FACTOR BETA;

CARCINOID; CARCINOID SYNDROME; FIBROSIS; HEART MUSCLE FIBROSIS; HUMAN; INCIDENCE; INTESTINAL FIBROSIS; LUNG FIBROSIS; PATHOPHYSIOLOGY; PLEURAL FIBROSIS; PREVALENCE; PRIORITY JOURNAL; RETROPERITONEAL FIBROSIS; REVIEW; SKIN FIBROSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

CARCINOID TUMOR; FIBROSIS; HUMANS; SEROTONIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 67651174571     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.51     Document Type: Review

References (72)

1. Modlin, I. M., Shapiro, M. D. & Kidd, M. siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum. Pathol. 35, 1440-1451 (2004).
2. Kloppel, G., Perren, A. & Heitz, P. U. The gastroenteropancreatic neuroendocrine cell system and its tumors: the wHO classification. Ann. NY Acad. Sci. 1014, 13-27 (2004).
3. Modlin, I. M., Kidd, M., Latich, I., Zikusoka, M. N. & shapiro, M. D. Current status of gastrointestinal carcinoids. Gastroenterology 128, 1717-1751 (2005).
4. Eriksson, B., et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors-well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 87, 8-19 (2008). (Pubitemid 350308290)
5. Modlin, I. M., shapiro, M. D. & Kidd, M. Carcinoid tumors and fibrosis: an association with no explanation. Am. J. Gastroenterol. 99, 2466-2478 (2004).
6. Morgan, J. G., Marks, C. & Hearn, D. Carcinoid tumors of the gastrointestinal tract. Ann. Surg. 180, 720-727 (1974).
7. Kidd, M., shapiro, M. D. & Lye, K. D. Connective tissue growth factor (CTGF) is overexpressed in ileal carcinoids. Presented at the Gastrointestinal Cancers symposium of the American Society of Clinical Oncology, January 22-24, san Francisco, California, UsA (2004).
8. Hellman, P., et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J. Surg. 26, 991-997 (2002).
9. Cai, Y. C., et al. Florid angiogenesis in mucosa surrounding an ileal carcinoid tumor expressing transforming growth factor-á. Am. J. Surg. Pathol. 21, 1373-1377 (1997).
10. Kottra, J. J. & Dunnick, N. R. retroperitoneal fibrosis. Radiol. Clin. North Am. 34, 1259-1275 (1996).
11. Dev., S., Al Dujaily, S. & subbuswamy, S. G. A case of ureteric obstruction, retroperitoneal fibrosis, and carcinoid tumour. Postgrad. Med. J. 75, 38-40 (1999).
12. Morand, J. J., et al. edema caused by retroperitoneal and tricuspid fibrosis with sclerodermatous cutaneous involvement disclosing carcinoid tumor. Apropos of a case and review of the literature [French]. Rev. Med. Interne. 18, 388-395 (1997).
13. Nelson, D. R. stachura, M. E. & Dunlap, D. B. Ileal carcinoid tumor complicated by retroperitoneal fibrosis and a prolactinoma. Am. J. Med. Sci. 296, 129-133 (1988).
14. Scott, J., Foster, R. & Moore, A. retroperitoneal fibrosis and nonmalignant ileal carcinoid. J. Urol. 138, 1435 (1987).
15. Gupta, A., Saibil, F., Kassim, O. & McKee, J. retroperitoneal fibrosis caused by carcinoid tumour. Q. J. Med. 56, 367-375 (1985).
16. Moss, S. F., et al. Pleural involvement in the carcinoid syndrome. Q. J. Med. 86, 49-53 (1993).
17. Tamagno, G., Goglia, U., Villa, G. & Murialdo, G. Lung fibrosis in carcinoid syndrome. Intern. Med. 46, 425-426 (2007).
18. Seo, J. W., Im, J. G., Kim, Y. W., Kim, J. H. & Sheppard, M. N. Synchronous double primary lung cancers of squamous and neuroendocrine type associated with cryptogenic fibrosing alveolitis. Thorax 46, 857-858 (1991).
19. Miller, R. R. & Muller, N. L. Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am. J. Surg. Pathol. 19, 653-658 (1995).
20. Kucuk, O., et al. Lower extremity vasospasm associated with ischemic neuropathy, dermal fibrosis, and digital gangrene in a patient with carcinoid syndrome. Cancer 62, 1026-1029 (1988).
21. Bell, H. K., Poston, G. J., Vora, J. & Wilson, N. J. Cutaneous manifestations of the malignant carcinoid syndrome. Br. J. Dermatol. 152, 71-75 (2005).
22. Ratnavel, R. C., Burrows, N. P. & Pye, R. J. scleroderma and the carcinoid syndrome. Clin. Exp. Dermatol. 19, 83-85 (1994).
23. Thorson, A., Biorck, G., Bjorkman, G. & waldenstrom, J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am. Heart J. 47, 795-817 (1954).
24. Ferrans, V. J. & Roberts, W. C. The carcinoid endocardial plaque; an ultrastructural study. Hum. Pathol. 7, 387-409 (1976).
25. Norheim, I., et al. Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival. Ann. Surg. 206, 115-125 (1987).
26. Lundin, L., Norheim, I., Landelius, J., Oberg, K. & Theodorsson-Norheim, E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation 77, 264-269 (1988).
27. Bhattacharyya, S., Toumpanakis, C., Caplin, M. E. & Davar, J. Analysis of 150 patients with carcinoid syndrome seen in a single year at one institution in the first decade of the twenty-first century. Am. J. Cardiol. 101, 378-381 (2008).
28. Bhattacharyya, S., Davar, J., Dreyfus, G. & Caplin, M. E. Carcinoid heart diseasE. Circulation 116, 2860-2865 (2007).
29. Howard, R. J., et al. Carcinoid heart disease: diagnosis by two-dimensional echocardiography. Circulation 66, 1059-1065 (1982).
30. Zanettini, R., et al. valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356, 39-46 (2007).
31. Bader, T. R. semelka, R. C., Chiu, V. C., Armao, D. M. & woosley, J. T. Mri of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver. J. Magn. Reson. Imaging 14, 261-269 (2001).
32. Woodard, P. K., Feldman, J. M., Paine, S. S. & Baker, M. E. Midgut carcinoid tumors: CT findings and biochemical profiles. J. Comput. Assist. Tomogr. 19, 400-405 (1995).
33. Pantongrag-Brown, L., Buetow, P. C., Carr, N. J., Lichtenstein, J. E. & Buck, J. L. Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation. AJR Am. J. Roentgenol. 164, 387-391 (1995).
34. Horton, K. M., Lawler, L. P. & Fishman, E. K. CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. Radiographics 23, 1561-1567 (2003).
35. Levy, A. D., Rimola, J., Mehrotra, A. K. & Sobin, L. H. From the archives of the AFiP: benign fibrous tumors and tumorlike lesions of the mesentery: radiologic-pathologic correlation. Radiographics 26, 245-264 (2006).
36. Coulier, B., et al. Carcinoid tumor of the small intestine: MDCT findings with pathologic correlation. JBR-BTR 90, 507-515 (2007).
37. Lesurtel, M., Soll, C., Graf, R. & Clavien, P. A. Role of serotonin in the hepato-gastrointestinal tract: an old molecule for new perspectives. Cell. Mol. Life Sci. 65, 940-952 (2008).
38. Barnes, N. M. & Sharp, T. A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083-1152 (1999).
39. Kim, D. Y. & Camilleri, M. Serotonin: A mediator of the brain-gut connection. Am. J. Gastroenterol. 95, 2698-2709 (2000).
40. Launay, J. M., et al. ras involvement in signal transduction by the serotonin 5-HT2B receptor. J. Biol. Chem. 271, 3141-3147 (1996).
41. Nebigil, C. G., Launay, J. M., Hickel, P., Tournois, C. & Maroteaux, L. 5-hydroxytryptamine 2B receptor regulates cellcycle progression: crosstalk with tyrosine kinase pathways. Proc. Natl Acad. Sci. USA 97, 2591-2596 (2000).
42. Mason, J. W., Billingham, M. E. & Friedman, J. P. Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis. Circulation 56, 889-890 (1977).
43. Connolly, H., et al. valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337, 581-588 (1997). (Pubitemid 27360757)
44. Antonini, A. & Poewe, W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 6, 826-829 (2007).
45. Jagroop, I. A. & Mikhailidis, D. P. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets 11, 161-165 (2000).
46. Gustafsson, B. I., et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 111, 1517-1522 (2005).
47. Mekontso-Dessap, A., et al. Deficiency of the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113, 81-89 (2006).
48. Musunuru, S., Carpenter, J. E., sippel, R. S., Kunnimalaiyaan, M. & Chen, H. A mouse model of carcinoid syndrome and heart disease. J. Surg. Res. 126, 102-105 (2005).
49. Wang, B., et al. Regulation of collagen synthesis by inhibitory smad7 in cardiac myofibroblasts. Am. J. Physiol. Heart Circ. Physiol. 293, H1282-H1290 (2007).
50. Ruddell, R. G., et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am. J. Pathol. 169, 861-876 (2006).
51. Caplin, M. E., et al. Carcinoid tumour. Lancet 352, 799-805 (1998).
52. Kulke, M. H. & Mayer, R. J. Carcinoid tumors. N. Engl. J. Med. 340, 858-868 (1999).
53. Jian, B., et al. serotonin mechanisms in heart valve disease I: Serotonin-induced upregulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. Am. J. Pathol. 161, 2111-2121 (2002).
54. Moller, J. E., et al. Factors associated with progression of carcinoid heart disease. N. Engl. J. Med. 348, 1005-1015 (2003).
55. Nilsson, C. L., Brodin, E. & Ekman, R. substance P and related peptides in porcine cortex: whole tissue and nuclear localization. J. Chromatogr. A 800, 21-27 (1998).
56. Chaudhry, A., Funa, K. & Oberg, K. Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system. Acta Oncol. 32, 107-114 (1993).
57. Waltenberger, J., et al. involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. Am. J. Pathol. 142, 71-78 (1993).
58. Kidd, M., et al. CTGF, intestinal stellate cells and carcinoid fibrogenesis. World J. Gastroenterol. 13, 5208-5216 (2007).
59. Lal, A. & Chen, H. Treatment of advanced carcinoid tumors. Curr. Opin. Oncol. 18, 9-15 (2006).
60. Bhattacharyya, S., Toumpanakis, C., Caplin, M. E. & Davar, J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am. J. Cardiol. 102, 938-942 (2008).
61. Ohrvall, U., et al. Method for dissection of mesenteric metastases in midgut carcinoid tumors. World J. Surg. 24, 1402-1408 (2000).
62. Howell, S. B., et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97, 845-851 (1982).
63. Moertel, C. G., Kvols, L. K. & rubin, J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 67, 33-36 (1991).
64. Robertson, J. I. Carcinoid syndrome and serotonin: therapeutic effects of ketanserin. Cardiovasc. Drugs Ther. 4 (Suppl. 1), s53-s58 (1990).
65. Noppen, M., Jacobs, A., Van Belle, S., Herregodts, P. & Somers, G. Inhibitory effects of ranitidine on flushing and serum serotonin concentrations in carcinoid syndrome. Br. Med. J. (Clin. Res. Ed.) 296, 682-683 (1988).
66. Wymenga, A. N., De Vries, E. G., Leijsma, M. K., Kema, I. P. & Kleibeuker, J. H. effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome. Eur. J. Cancer 34, 1293-1294 (1998).
67. Jacobsen, M. B. Ondansetron in carcinoid syndrome. Lancet 340, 185 (1992).
68. Hauso, O., et al. Long-term serotonin effects in the rat are prevented by terguride. Regul. Pept. 143, 39-46 (2007).
69. Ciccarelli, E., Touzel, R. Besser, M. & Grossman, A. Terguride-a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. Fertil. Steril. 49, 589-594 (1988).
70. Greenblatt, D. Y., et al. Valproic acid activates Notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 12, 942-951 (2007).
71. Kunnimalaiyaan, M. & Chen, H. The raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 17, 139-142 (2006).
72. Brown, P., Pappas, C., Frazier, K., Turnage, A. & Liu, Q. LX1032: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome. [Abstract C16] Presented at the 6th Annual Conference of the european Neuroendocrine Tumor society: 2009 March 5-7, Granada, spain.